6533b827fe1ef96bd1285ddf
RESEARCH PRODUCT
Targeted Therapies for Colorectal Cancer
Giuseppe BronteMarc PeetersAntonio RussoAntonio Galvanosubject
CetuximabBevacizumabbusiness.industryColorectal cancermedicine.diseaseOxaliplatinIrinotecanRegimenchemistry.chemical_compoundchemistryRegorafenibmedicineCancer researchPanitumumabHuman medicinebusinessmedicine.drugdescription
In the last decades, the standard chemotherapeutic approach for the metastatic colorectal cancer (mCRC) treatment was represented by a 5-FU-based regimen with the addition of either oxaliplatin or irinotecan. Recent discoveries in the molecular biology field led to the spread of so-called targeted agents whose mechanism of action is based on the binding with specific target molecules (cellular receptors or soluble proteins) responsible for the activation of many transduction pathways required for malignant cell growth and survival. Among these, the most important consist of monoclonal antibodies (mAbs) and the tyrosine kinase inhibitors (TKIs). As a consequence, the different mechanism of action of these new drugs involves a variability of improved outcomes achieved and tolerability profile. These new chemotherapy options will represent in the next future the milestone of a new biological era for the treatment of mCRC patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-01 |